Study wrapper · #449
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
Editor's note
An indirect comparison using multilevel network meta-regression to weigh injectable tirzepatide against daily oral semaglutide 50 mg for weight management, anchoring on the SURMOUNT-1 and OASIS 1 trials and adjusting for population differences. Tirzepatide 10 and 15 mg were associated with statistically greater weight and waist-circumference reductions and higher odds of hitting >=5–20% weight-loss thresholds than oral semaglutide, with cardiometabolic and safety profiles described as improved or comparable. The ranking is consistent with the broader record on these two agents. The central caveat is in the method: this is an indirect, cross-trial comparison, not a head-to-head trial; the two pivotal studies differed in design and duration, and adjustment can reduce but not remove that mismatch. Read as a reasonable model-based estimate favoring higher-dose tirzepatide on weight, pending direct comparative data, which does not yet exist.
Plain-language abstract
No trial has directly compared injectable tirzepatide with the daily oral form of semaglutide for weight loss, so researchers used a statistical method to compare them indirectly. They took results from two major trials, one of tirzepatide and one of oral semaglutide, and adjusted for differences between the groups of people studied, such as sex and ethnicity. The analysis found that tirzepatide at 10 mg and 15 mg was linked to greater weight loss and more waistline reduction than oral semaglutide, and more people reached weight-loss targets of 5% to 20%. Benefits for heart-and-metabolism measures and side-effect profiles were similar or somewhat better with tirzepatide. Because this compares drugs across separate trials rather than testing them side by side in the same study, the results are estimates rather than direct evidence. The authors note a true head-to-head trial would be needed to confirm the comparison.